Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month Low – What’s Next?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price reached a new 52-week low on Friday . The stock traded as low as $272.00 and last traded at $271.6850, with a volume of 390019 shares trading hands. The stock had previously closed at $283.15.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research report on Friday, May 1st. HC Wainwright upped their target price on shares of Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a report on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $455.31.

Alnylam Pharmaceuticals Price Performance

The company has a market cap of $36.11 billion, a price-to-earnings ratio of 73.81 and a beta of 0.27. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The company has a 50 day moving average price of $294.71 and a 200-day moving average price of $321.49.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the firm posted ($0.44) earnings per share. The firm’s revenue was up 96.4% on a year-over-year basis. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its stake in shares of Alnylam Pharmaceuticals by 20.8% during the second quarter. Assenagon Asset Management S.A. now owns 155,695 shares of the biopharmaceutical company’s stock worth $46,869,000 after acquiring an additional 26,799 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock worth $295,000 after buying an additional 65 shares during the period. Glenmede Trust Co. NA raised its holdings in shares of Alnylam Pharmaceuticals by 8.3% during the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 56 shares in the last quarter. Groupama Asset Managment boosted its stake in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock valued at $12,165,000 after purchasing an additional 889 shares in the last quarter. Finally, Segall Bryant & Hamill LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $641,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.